1. Home
  2. MSEX vs RAPP Comparison

MSEX vs RAPP Comparison

Compare MSEX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middlesex Water Company

MSEX

Middlesex Water Company

HOLD

Current Price

$57.76

Market Cap

984.5M

Sector

Utilities

ML Signal

HOLD

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$43.33

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSEX
RAPP
Founded
1897
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
984.5M
2.3B
IPO Year
1995
2024

Fundamental Metrics

Financial Performance
Metric
MSEX
RAPP
Price
$57.76
$43.33
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$61.33
$48.50
AVG Volume (30 Days)
100.7K
248.6K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
2.77%
N/A
EPS Growth
N/A
24.34
EPS
1.36
N/A
Revenue
$194,694,000.00
N/A
Revenue This Year
$10.60
N/A
Revenue Next Year
$10.94
N/A
P/E Ratio
$42.48
N/A
Revenue Growth
1.47
N/A
52 Week Low
$44.94
$22.75
52 Week High
$62.18
$52.93

Technical Indicators

Market Signals
Indicator
MSEX
RAPP
Relative Strength Index (RSI) 48.70 39.90
Support Level $56.83 $38.95
Resistance Level $58.43 $43.99
Average True Range (ATR) 1.05 2.15
MACD -0.16 -0.87
Stochastic Oscillator 31.65 7.70

Price Performance

Historical Comparison
MSEX
RAPP

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: